1. LBA10Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. (24th November 2019) Authors: Fujiwara, K; Harter, P; Leary, A; Perol, D; Pignata, S; González-Martín, A; Petru, E; van Nieuwenhuysen, E; Colombo, N; Mäenpää, J; Selle, F; de Gregorio, N; Lorusso, D; Guerra Alia, E M; Lefeuvre-Plesse, C; Buderath, P; Lortholary, A; Burges, A; Pujade-Lauraine, E; Ray-Coquard, I L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dilution of molecular-pathologic gene signatures (MPG) by parameter unrelated to tumor biology (UTB) may prevent prediction of the resection status after debulking surgery in patients with advanced ovarian cancer. (1st November 2019) Authors: Heitz, F; Kommoss, S; Tourani, R; Grandelis, A; Uppendahl, L; Aliferis, C; Burges, A; Wang, C; Canzler, U; Wang, J; Belau, A; Prader, S; Hanker, L; Ma, S; Ataseven, B; Hilpert, F; Schneider, S; Sehouli, J; Kimmig, R; Kurzeder, C Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗